- Bausch Health Companies press release ( NYSE: BHC ): Q4 GAAP EPS of -$1.13.
- Revenue of $2.2B (flat Y/Y) beats by $60M .
- Adjusted EBITDAattributable to Bausch Health (non-GAAP)Adjusted EBITDA attributable to Bausch Health (non-GAAP ) 1 was $823 million for the fourth quarter and $3,022 million for the full year of 2022, compared with $909 million for the fourth quarter and $3,472 million for the full year of 2021, a decrease of $86 million in the quarter and $450 million for the full year.
- Guidance: The Company is not providing consolidated full year guidance, as Bausch + Lomb has not provided full year guidance. Bausch Health (excl. B+L) has provided guidance for the full year of 2023 as follows:
- Full-year revenue range of $4.45 - $4.6 billion
- Full-year adjusted EBITDA (non-GAAP) 1 range of $2.3 - $2.4 billion
For further details see:
Bausch Health Companies GAAP EPS of -$1.13 misses, revenue of $2.2B beats by $60M